iRhythm Technologies Announces Chief Financial Officer Transition

Rhea-AI Summary

iRhythm Technologies (NASDAQ: IRTC) announced a leadership transition in its finance department. Brice Bobzien, the current CFO, will step down on August 31, 2024, for personal reasons. He will be succeeded by Daniel Wilson, the company's Executive Vice President of Corporate Development and Investor Relations. Bobzien, who has served as CFO since 2022, will continue in an advisory role into 2025 to ensure a smooth transition.

CEO Quentin Blackford praised Bobzien's contributions in transforming iRhythm's finance organization and positioning the company for growth. Wilson, who has been with iRhythm since 2019, brings extensive experience in corporate development, strategy, and investor relations. His background includes roles at Penumbra, J.P. Morgan, and Piper Jaffray, focusing on healthcare and medical technology sectors.

Positive

• Smooth leadership transition planned with current CFO staying on in advisory role
• New CFO Daniel Wilson brings extensive experience in healthcare and finance sectors
• Wilson's familiarity with iRhythm since 2019 suggests continuity in financial strategy

Negative

• Departure of current CFO Brice Bobzien after only two years in the role

SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company in an advisory capacity into 2025 following the succession to ensure a smooth transition.

“Brice has been an outstanding leader at iRhythm over the past two years, making significant contributions to transform iRhythm’s finance organization during his tenure with the company,” said Quentin Blackford, iRhythm’s President and CEO. “He has been invaluable in helping position our company to operate efficiently and effectively ahead of immense growth, leading with a disciplined and rigorous approach to financial management, operational excellence, and strategic development. We wish him all the best as he shifts his attention towards personal and family matters.”

“At the same time, we are thrilled to have Dan take over the finance organization and are confident in the expanded leadership he will provide as our next CFO. Dan has a long history with iRhythm, advising the company on its initial public offering and then joining iRhythm in 2019. In his time with the company, Dan has been a trusted partner, strategic leader, unwavering brand ambassador, and a passionate champion of iRhythm’s mission. His strong strategic background, industry experience, and financial acumen make him uniquely qualified to help lead the organization into our next phase of growth.”

Mr. Wilson has served as iRhythm’s Executive Vice President of Corporate Development and Investor Relations since April 2023 and previously served as Executive Vice President of Corporate Development, Corporate Strategy, and Investor Relations since June 2019. Previously, he served as Director and Head of Business Development at Penumbra, Inc., a global healthcare company focused on innovative therapies. Prior to Penumbra, he held various positions at J.P. Morgan between August 2006 and May 2016, most recently as Executive Director in the Healthcare Investment Banking group focused on digital health, medical technology, and emerging healthcare companies. Earlier in his career, he held various positions in Piper Jaffray’s Healthcare Investment Banking group. He started his career at KPMG as an Audit Associate. Mr. Wilson has a B.S. in Business Administration from California Polytechnic State University at San Luis Obispo.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Relations Contact
Stephanie Zhadkevich
investors@irhythmtech.com

Media Contact
Kassandra Perry
irhythm@highwirepr.com

FAQ

When will Brice Bobzien step down as CFO of iRhythm Technologies (IRTC)?

Brice Bobzien will step down as CFO of iRhythm Technologies (IRTC) effective August 31, 2024.

Who will succeed Brice Bobzien as CFO of iRhythm Technologies (IRTC)?

Daniel Wilson, iRhythm's current Executive Vice President of Corporate Development and Investor Relations, will succeed Brice Bobzien as CFO.

What is Daniel Wilson's background before joining iRhythm Technologies (IRTC)?

Before joining iRhythm, Daniel Wilson held positions at Penumbra, J.P. Morgan's Healthcare Investment Banking group, and Piper Jaffray's Healthcare Investment Banking group.

How long has Brice Bobzien served as CFO of iRhythm Technologies (IRTC)?

Brice Bobzien has served as CFO of iRhythm Technologies (IRTC) since 2022, which is approximately two years.